X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Fresenius Kabi Onco. with VENUS REMEDIES - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

FRESENIUS KABI ONCO. vs VENUS REMEDIES - Comparison Results

FRESENIUS KABI ONCO.    Change

Fresenius Kabi Oncology is the erstwhile Dabur Pharma, which was incorporated in March 2003. The company is a leading player in oncology in India and the international markets. Fresenius Kabi Oncology operates in the regulated markets namely the US a... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    FRESENIUS KABI ONCO. VENUS REMEDIES FRESENIUS KABI ONCO./
VENUS REMEDIES
 
P/E (TTM) x 22.1 -836.6 - View Chart
P/BV x 3.1 0.2 1,272.4% View Chart
Dividend Yield % 0.0 0.0 -  

Financials

 FRESENIUS KABI ONCO.   VENUS REMEDIES
EQUITY SHARE DATA
    FRESENIUS KABI ONCO.
Mar-13
VENUS REMEDIES
Mar-16
FRESENIUS KABI ONCO./
VENUS REMEDIES
5-Yr Chart
Click to enlarge
High Rs176218 80.7%   
Low Rs7982 95.6%   
Sales per share (Unadj.) Rs37.7365.6 10.3%  
Earnings per share (Unadj.) Rs5.11.5 342.7%  
Cash flow per share (Unadj.) Rs6.737.9 17.7%  
Dividends per share (Unadj.) Rs00-  
Dividend yield (eoy) %00-  
Book value per share (Unadj.) Rs42.5382.5 11.1%  
Shares outstanding (eoy) m158.2311.44 1,383.1%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x3.40.4 822.8%   
Avg P/E ratio x25.0101.0 24.7%  
P/CF ratio (eoy) x18.94.0 478.3%  
Price / Book Value ratio x3.00.4 762.5%  
Dividend payout %00-   
Avg Mkt Cap Rs m20,1351,717 1,173.0%   
No. of employees `0001.21.0 112.9%   
Total wages/salary Rs m703324 216.8%   
Avg. sales/employee Rs Th5,176.24,100.7 126.2%   
Avg. wages/employee Rs Th610.4318.0 191.9%   
Avg. net profit/employee Rs Th699.616.7 4,197.4%   
INCOME DATA
Net Sales Rs m5,9634,183 142.6%  
Other income Rs m1820 89.6%   
Total revenues Rs m5,9814,203 142.3%   
Gross profit Rs m1,430812 176.2%  
Depreciation Rs m258417 61.9%   
Interest Rs m-26380 -6.8%   
Profit before tax Rs m1,21635 3,465.0%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m-680-   
Tax Rs m34218 1,890.6%   
Profit after tax Rs m80617 4,740.6%  
Gross profit margin %24.019.4 123.6%  
Effective tax rate %28.151.6 54.6%   
Net profit margin %13.50.4 3,325.2%  
BALANCE SHEET DATA
Current assets Rs m5,1022,771 184.1%   
Current liabilities Rs m2,3851,931 123.5%   
Net working cap to sales %45.620.1 227.0%  
Current ratio x2.11.4 149.1%  
Inventory Days Days150125 120.0%  
Debtors Days Days11354 210.8%  
Net fixed assets Rs m5,1485,328 96.6%   
Share capital Rs m158114 138.3%   
"Free" reserves Rs m6,5564,177 156.9%   
Net worth Rs m6,7324,376 153.8%   
Long term debt Rs m9521,911 49.8%   
Total assets Rs m10,3888,428 123.3%  
Interest coverage x-45.81.1 -4,190.4%   
Debt to equity ratio x0.10.4 32.4%  
Sales to assets ratio x0.60.5 115.7%   
Return on assets %7.54.7 159.5%  
Return on equity %12.00.4 3,081.8%  
Return on capital %14.66.6 221.3%  
Exports to sales %74.50-   
Imports to sales %24.820.5 120.7%   
Exports (fob) Rs m4,441NA-   
Imports (cif) Rs m1,477858 172.1%   
Fx inflow Rs m5,2980-   
Fx outflow Rs m1,772858 206.5%   
Net fx Rs m3,525-858 -410.7%   
CASH FLOW
From Operations Rs m1,274469 271.8%  
From Investments Rs m-1,20429 -4,124.0%  
From Financial Activity Rs m-196-464 42.3%  
Net Cashflow Rs m-12635 -366.1%  

Share Holding

Indian Promoters % 0.0 32.9 -  
Foreign collaborators % 81.0 0.0 -  
Indian inst/Mut Fund % 0.3 0.2 166.7%  
FIIs % 9.6 0.6 1,655.2%  
ADR/GDR % 0.0 0.0 -  
Free float % 9.1 66.4 13.7%  
Shareholders   42,599 20,121 211.7%  
Pledged promoter(s) holding % 0.0 36.4 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare FRESENIUS KABI ONCO. With:   SHASUN PHARMA  WYETH LTD  ABBOTT INDIA  UNICHEM LAB  DR. REDDYS LAB  

Compare FRESENIUS KABI ONCO. With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Of Global Markets Hitting Record Highs and Top Stocks in Action During the Week(RoundUp)

Global stock markets ended the week on a positive note. Benchmark indices in US grew by 1% during the week. The Down Jones Industrial Average topped the 26,000.

Related Views on News

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

Sun Pharma: Tough US Scenario Continues to Hit Business (Quarterly Results Update - Detailed)

Nov 20, 2017

The company's India business recovers but the pricing pressure and USFDA issues continue to mar the US revenues.

Dr Reddy's: No Respite from Pricing Pressure in the US (Quarterly Results Update - Detailed)

Nov 13, 2017

Pricing pressure continued to haunt Dr Reddy's although there was a significant improvement in its businesses sequentially.

Cipla: Strong Recovery Post GST (Quarterly Results Update - Detailed)

Nov 10, 2017

Cipla's India business recovers strongly this quarter post the GST issues in the first quarter of this fiscal.

Glenmark: Most Geographies Show Weak Growth (Quarterly Results Update - Detailed)

Nov 7, 2017

Poor show in the US, Latam and India hit profits during the quarter.

More Views on News

Most Popular

Retail Investors or Chickens Waiting to Get Slaughtered in the Stock Market?(Vivek Kaul's Diary)

Jan 9, 2018

The price to earnings ratio of the Nifty 50 is very close to all-time high levels.

Best ELSS Funds In 2018: Don't Blindly Chase Top Performers(Outside View)

Jan 10, 2018

As the tax-saving season begins, investors hunt for the best ELSS funds for 2018. PersonalFN provides a list of the top ELSS mutual funds of the past year.

Did GST and Notebandi Help? Sherlock Holmes Finds Out...(The 5 Minute Wrapup)

Jan 13, 2018

Discussions with my cousin helped me understand the situation on Ground Zero - after the demonetization and GST upheaval. Here's what that means for listed companies...

Resolutions for 2018 - by others(The Honest Truth)

Jan 8, 2018

Ten quirky new year resolutions. Guess by whom?

Bitcoin Beginners Should Do These Three Things...(Smart Contrarian)

Jan 10, 2018

Three simple points to keep in mind before you consider buying bitcoin.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

FRESENIUS KABI ONCO. SHARE PRICE


Jan 2, 2014 (Close)

TRACK FRESENIUS KABI ONCO.

  • Track your investment in FRESENIUS KABI ONCO. with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON FRESENIUS KABI ONCO.

FRESENIUS KABI ONCO. - LUPIN LTD COMPARISON

COMPARE FRESENIUS KABI ONCO. WITH

MARKET STATS